JOURNAL ARTICLE

Eli Lilly Executive Who Oversaw Development of Blockbuster Diabetes Drug Is Set to Retire.

  • Published In: Bloomberg.com, 2023. P. N.PAG 1 of 3

  • Database: Business Source Ultimate 2 of 3

  • Authored By: Lauerman, John 3 of 3

Abstract

(Bloomberg) -- The Eli Lilly & Co. executive who oversaw development of Mounjaro, its blockbuster diabetes medicine that's also used for weight loss, will retire at the end of the year. Read More: All About the New Obesity Drugs Causing a Big Stir Long a leader in diabetes, Lilly has seen GLP-1 diabetes medications that also help patients lose weight become a huge driver of growth. [Extracted from the article]

Additional Information

  • Source:Bloomberg.com. 2023/10, pN.PAG
  • Document Type:Article
  • Subject Area:Health and Medicine
  • Publication Date:2023
  • Accession Number:172773721
  • Copyright Statement:Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.